Literature DB >> 16109501

Intrahepatic immunity: a tale of two sites?

David G Bowen1, Geoffrey W McCaughan, Patrick Bertolino.   

Abstract

The intrahepatic immune environment is associated with the induction of tolerance, yet maintains the capacity to sustain effective responses against pathogens. The mechanisms underlying this dichotomy are unclear. Recent data indicate that activation of naïve CD8(+) T cells occurs within the liver. However, in contrast to efficient primary activation observed within the lymph nodes, this pathway is relatively ineffective, leading to reduced CD8(+) T-cell cytotoxicity and survival. Thus, the outcome of intrahepatic CD8(+) T-cell responses might be determined by whether primary activation occurs within the tolerogenic environment of the liver, or whether immunity is induced by initial antigen encounter within the lymph nodes. These findings support a novel model of hepatic-immune interactions, with implications for our understanding of the paradoxical nature of liver immunobiology.

Entities:  

Mesh:

Year:  2005        PMID: 16109501     DOI: 10.1016/j.it.2005.08.005

Source DB:  PubMed          Journal:  Trends Immunol        ISSN: 1471-4906            Impact factor:   16.687


  32 in total

1.  Peripheral immunization induces functional intrahepatic hepatitis C specific immunity following selective retention of vaccine-specific CD8 T cells by the liver.

Authors:  Krystle A Lang Kuhs; Roberta Toporovski; Arielle A Ginsberg; Abby L Olsen; Devon J Shedlock; Matthew P Morrow; Jian Yan; Rebecca G Wells; David B Weiner
Journal:  Hum Vaccin       Date:  2011-12-01

Review 2.  The role of chemokines in the recruitment of lymphocytes to the liver.

Authors:  Ye H Oo; Shishir Shetty; David H Adams
Journal:  Dig Dis       Date:  2010-05-07       Impact factor: 2.404

3.  High-dose immunoembolization: survival benefit in patients with hepatic metastases from uveal melanoma.

Authors:  Akira Yamamoto; Inna Chervoneva; Kevin L Sullivan; David J Eschelman; Carin F Gonsalves; Michael J Mastrangelo; David Berd; Jerry A Shields; Carol L Shields; Mizue Terai; Takami Sato
Journal:  Radiology       Date:  2009-07       Impact factor: 11.105

4.  Selective expansion of allogeneic regulatory T cells by hepatic stellate cells: role of endotoxin and implications for allograft tolerance.

Authors:  Anil Dangi; Tina L Sumpter; Shoko Kimura; Donna B Stolz; Noriko Murase; Giorgio Raimondi; Yoram Vodovotz; Chao Huang; Angus W Thomson; Chandrashekhar R Gandhi
Journal:  J Immunol       Date:  2012-03-16       Impact factor: 5.422

Review 5.  Combined locoregional-immunotherapy for liver cancer.

Authors:  Tim F Greten; Michal Mauda-Havakuk; Bernd Heinrich; Firouzeh Korangy; Bradford J Wood
Journal:  J Hepatol       Date:  2019-02-07       Impact factor: 25.083

Review 6.  Chemokines in the immunopathogenesis of hepatitis C infection.

Authors:  Mathis Heydtmann; David H Adams
Journal:  Hepatology       Date:  2009-02       Impact factor: 17.425

7.  D-penicillamine-induced granulomatous hepatitis in brown Norway rats.

Authors:  Imir G Metushi; Xu Zhu; Jack Uetrecht
Journal:  Mol Cell Biochem       Date:  2014-04-27       Impact factor: 3.396

Review 8.  Hepatitis C virus and ethanol alter antigen presentation in liver cells.

Authors:  Natalia A Osna
Journal:  World J Gastroenterol       Date:  2009-03-14       Impact factor: 5.742

9.  Immunostimulatory properties of dendritic cells after Leishmania donovani infection using an in vitro model of liver microenvironment.

Authors:  Ludovic Donaghy; Florian Cabillic; Anne Corlu; Octavie Rostan; Olivier Toutirais; Christiane Guguen-Guillouzo; Claude Guiguen; Jean-Pierre Gangneux
Journal:  PLoS Negl Trop Dis       Date:  2010-06-08

10.  Isolation of murine intrahepatic immune cells employing a modified procedure for mechanical disruption and functional characterization of the B, T and natural killer T cells obtained.

Authors:  K G Blom; M Rahman Qazi; J B Noronha Matos; B D Nelson; J W DePierre; M Abedi-Valugerdi
Journal:  Clin Exp Immunol       Date:  2008-11-24       Impact factor: 4.330

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.